Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Marie-Pier St-Laurent, MD, FRCSC
Advertisement
St-Laurent is a urologic oncologist at the University of British Columbia in Vancouver, Canada.
Articles by Marie-Pier St-Laurent, MD, FRCSC
NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in patients with MIBC with complete response to neoadjuvant therapy.
Advertisement
Latest Updated Articles
NeoBLAST trial tests active surveillance after complete response in MIBCSeptember 4th 2026
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
2
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
3
Matching mCSPC treatment to the patient, not just the trial data
4
Urocross Expander System enters US commercial use for symptomatic BPH
5